Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.94
(-6.62%)
USD 0.94
(-6.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 232.12 Million USD | 44.84% |
| 2022 | 160.25 Million USD | -11.72% |
| 2021 | 181.53 Million USD | -20.4% |
| 2020 | 228.06 Million USD | -20.67% |
| 2019 | 287.49 Million USD | -30.88% |
| 2018 | 415.9 Million USD | 7.31% |
| 2017 | 387.56 Million USD | 23.53% |
| 2016 | 313.75 Million USD | 34.09% |
| 2015 | 233.99 Million USD | 6.25% |
| 2014 | 220.22 Million USD | -17.73% |
| 2013 | 267.68 Million USD | 20.55% |
| 2012 | 222.04 Million USD | 68.2% |
| 2011 | 132.01 Million USD | 26.18% |
| 2010 | 104.62 Million USD | -3.9% |
| 2009 | 108.87 Million USD | 39.33% |
| 2008 | 78.13 Million USD | 14.77% |
| 2007 | 68.07 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 62.9 Million USD | -13.39% |
| 2024 Q2 | 66.84 Million USD | 6.26% |
| 2023 Q3 | 69.03 Million USD | -94.14% |
| 2023 Q4 | 72.63 Million USD | 5.22% |
| 2023 Q1 | 43.96 Million USD | 13.2% |
| 2023 Q2 | 1.17 Billion USD | 2578.35% |
| 2023 FY | 232.12 Million USD | 44.84% |
| 2022 Q2 | 41.57 Million USD | 4.77% |
| 2022 Q3 | 40.16 Million USD | -3.4% |
| 2022 Q4 | 38.83 Million USD | -3.31% |
| 2022 FY | 160.25 Million USD | -11.72% |
| 2022 Q1 | 39.68 Million USD | -34.45% |
| 2021 Q4 | 60.53 Million USD | 56.64% |
| 2021 FY | 181.53 Million USD | -20.4% |
| 2021 Q2 | 39.21 Million USD | -9.09% |
| 2021 Q1 | 43.13 Million USD | -14.16% |
| 2021 Q3 | 38.64 Million USD | -1.44% |
| 2020 FY | 228.06 Million USD | -20.67% |
| 2020 Q3 | 56.62 Million USD | -0.17% |
| 2020 Q2 | 56.71 Million USD | -12.03% |
| 2020 Q1 | 64.47 Million USD | -1.9% |
| 2020 Q4 | 50.24 Million USD | -11.25% |
| 2019 Q1 | 118.73 Million USD | 15.89% |
| 2019 Q3 | 68.47 Million USD | -4.91% |
| 2019 Q4 | 65.72 Million USD | -4.01% |
| 2019 FY | 287.49 Million USD | -30.88% |
| 2019 Q2 | 72 Million USD | -39.36% |
| 2018 Q3 | 103.2 Million USD | -6.83% |
| 2018 FY | 415.9 Million USD | 7.31% |
| 2018 Q1 | 101.9 Million USD | 0.35% |
| 2018 Q2 | 110.77 Million USD | 8.7% |
| 2018 Q4 | 102.45 Million USD | -0.73% |
| 2017 Q4 | 101.54 Million USD | 0.8% |
| 2017 Q3 | 100.73 Million USD | 5.42% |
| 2017 FY | 387.56 Million USD | 23.53% |
| 2017 Q2 | 95.55 Million USD | 6.5% |
| 2017 Q1 | 89.72 Million USD | -0.69% |
| 2016 FY | 313.75 Million USD | 34.09% |
| 2016 Q4 | 90.35 Million USD | 5.4% |
| 2016 Q3 | 85.72 Million USD | 23.05% |
| 2016 Q2 | 69.66 Million USD | 2.43% |
| 2016 Q1 | 68.01 Million USD | 15.01% |
| 2015 Q4 | 59.13 Million USD | 5.09% |
| 2015 Q2 | 61.6 Million USD | 8.1% |
| 2015 Q3 | 56.26 Million USD | -8.66% |
| 2015 Q1 | 56.98 Million USD | -1.84% |
| 2015 FY | 233.99 Million USD | 6.25% |
| 2014 Q1 | 57.06 Million USD | 11.38% |
| 2014 Q3 | 53.65 Million USD | 4.31% |
| 2014 Q4 | 58.05 Million USD | 8.2% |
| 2014 FY | 220.22 Million USD | -17.73% |
| 2014 Q2 | 51.44 Million USD | -9.86% |
| 2013 FY | 267.68 Million USD | 20.55% |
| 2013 Q2 | 66.12 Million USD | -27.22% |
| 2013 Q3 | 59.46 Million USD | -10.08% |
| 2013 Q4 | 51.23 Million USD | -13.83% |
| 2013 Q1 | 90.85 Million USD | 29.95% |
| 2012 Q1 | 47.88 Million USD | 22.2% |
| 2012 FY | 222.04 Million USD | 68.2% |
| 2012 Q3 | 48.8 Million USD | -11.96% |
| 2012 Q2 | 55.43 Million USD | 15.78% |
| 2012 Q4 | 69.91 Million USD | 43.25% |
| 2011 Q2 | 30.21 Million USD | 4.99% |
| 2011 Q4 | 39.18 Million USD | 15.82% |
| 2011 FY | 132.01 Million USD | 26.18% |
| 2011 Q3 | 33.83 Million USD | 11.98% |
| 2011 Q1 | 28.77 Million USD | -2.67% |
| 2010 Q4 | 29.56 Million USD | 17.22% |
| 2010 FY | 104.62 Million USD | -3.9% |
| 2010 Q2 | 28.27 Million USD | 11.86% |
| 2010 Q1 | 25.28 Million USD | -22.78% |
| 2010 Q3 | 25.22 Million USD | -10.8% |
| 2009 FY | 108.87 Million USD | 39.33% |
| 2009 Q1 | 23.8 Million USD | 9.31% |
| 2009 Q2 | 25.18 Million USD | 5.82% |
| 2009 Q3 | 23.54 Million USD | -6.52% |
| 2009 Q4 | 32.73 Million USD | 39.05% |
| 2008 Q4 | 21.77 Million USD | 0.0% |
| 2008 FY | 78.13 Million USD | 14.77% |
| 2007 FY | 68.07 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -2712.645% |
| Alpha Teknova, Inc. | 45.85 Million USD | -406.169% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -18.441% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -417.51% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -45.799% |
| Cosmos Health Inc. | 26.18 Million USD | -786.62% |
| Journey Medical Corporation | 54.59 Million USD | -325.182% |
| Embecta Corp. | 528.4 Million USD | 56.07% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 14.628% |
| Dynavax Technologies Corporation | 219.14 Million USD | -5.923% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 60.657% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 28.879% |
| PainReform Ltd. | 9.58 Million USD | -2321.995% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1668.635% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1668.635% |
| SCYNEXIS, Inc. | 51.84 Million USD | -347.701% |
| Safety Shot Inc | 12.1 Million USD | -1816.844% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -7463.043% |
| Procaps Group, S.A. | 199.47 Million USD | -16.366% |
| Theratechnologies Inc. | 72.75 Million USD | -219.044% |
| Harrow Health, Inc. | 89.97 Million USD | -157.993% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2357.379% |
| Biofrontera Inc. | 39.95 Million USD | -480.905% |
| DURECT Corporation | 43.71 Million USD | -430.994% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 56.121% |
| Cronos Group Inc. | 96.7 Million USD | -140.023% |
| OptiNose, Inc. | 85.1 Million USD | -172.76% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -492.864% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2527.821% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 26.107% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2285.448% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -439.315% |
| Radius Health, Inc. | 265.92 Million USD | 12.712% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1576.965% |
| ProPhase Labs, Inc. | 37.85 Million USD | -513.241% |
| Phibro Animal Health Corporation | 260.29 Million USD | 10.824% |
| Procaps Group S.A. | 187.24 Million USD | -23.968% |
| Alvotech | 285.43 Million USD | 18.678% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2262.585% |
| Viatris Inc. | 5.96 Billion USD | 96.109% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1409.848% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -287.908% |
| SIGA Technologies, Inc. | 22.04 Million USD | -953.05% |
| Tilray Brands, Inc. | 251.35 Million USD | 7.652% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -373.355% |
| Shineco, Inc. | 17.94 Million USD | -1193.311% |
| PetIQ, Inc. | 192.72 Million USD | -20.443% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -5715.985% |
| Incannex Healthcare Limited | 30.05 Million USD | -672.382% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 85.46% |
| Alimera Sciences, Inc. | 62.64 Million USD | -270.562% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -30342.811% |
| Assertio Holdings, Inc. | 368.58 Million USD | 37.023% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -3843.95% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1203.443% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -996.528% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1003.141% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -40.71% |
| Hempacco Co., Inc. | 7.59 Million USD | -2955.691% |
| Talphera, Inc. | 11.99 Million USD | -1835.334% |
| Alvotech | 285.43 Million USD | 18.678% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -64.962% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 32.698% |
| Currenc Group, Inc. | 24 Million USD | -867.099% |
| Kamada Ltd. | 45.42 Million USD | -410.994% |
| Indivior PLC | 911 Million USD | 74.52% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1770.513% |
| Flora Growth Corp. | 10.57 Million USD | -2094.196% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1003.141% |
| Evolus, Inc. | 189.75 Million USD | -22.326% |
| HUTCHMED (China) Limited | 436.23 Million USD | 46.789% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -50.599% |
| Akanda Corp. | 3.48 Million USD | -6563.513% |